Management of "Hypertension" Based on Blood Pressure Level Versus an Absolute Cardiovascular Risk Approach

Area of Science:

• Cardiology
• Hypertension Management
• Clinical Trial Analysis

Background:

• The Systolic Blood Pressure Intervention Trial (SPRINT) showed benefits of lower blood pressure targets, including reduced mortality.
• Current US guidelines recommend a systolic blood pressure threshold of 130 mmHg, but this is not universally adopted.
• Clinicians express concerns about potential overtreatment of elevated blood pressure.

Purpose of the Study:

• To reconcile guideline recommendations with clinical trial evidence and clinician concerns regarding blood pressure management.
• To evaluate the appropriateness of current hypertension treatment thresholds and decision-making processes.
• To advocate for a risk-based approach in initiating blood pressure-lowering medication.

Main Methods:

• Review of clinical trial data, specifically the SPRINT trial.
• Analysis of current US hypertension guidelines and their recommendations.
• Discussion of the hybrid approach to treatment thresholds (risk-based vs. level-based).

Main Results:

• Lower blood pressure targets in SPRINT led to significant clinical benefits, including reduced all-cause mortality.
• Hypotension and other adverse events were observed with more intensive blood pressure lowering.
• The current US guideline's hybrid approach (risk stratification for 130s mmHg, level-based above 140 mmHg) is considered a compromise.

Conclusions:

• Risk stratification should be the primary basis for initiating blood pressure-lowering medication, except in cases of very high blood pressure.
• Treatment decisions should prioritize individuals most likely to experience cardiovascular events.
• A shift towards risk-based decision-making can help prevent the overtreatment of mildly elevated blood pressure.